These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1597212)

  • 1. In vitro susceptibility of Helicobacter pylori to nitecapone.
    Rautelin H; Renkonen OV; Kosunen TV
    Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):274-5. PubMed ID: 1597212
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of bismuth and nitecapone on acetaldehyde production by Helicobacter pylori.
    Salmela KS; Roine RP; Höök-Nikanne J; Kosunen TU; Salaspuro M
    Scand J Gastroenterol; 1994 Jun; 29(6):528-31. PubMed ID: 8079111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exercise hemodynamics and catecholamine metabolism after catechol-O-methyltransferase inhibition with nitecapone.
    Sundberg S; Scheinin M; Ojala-Karlsson P; Kaakkola S; Akkila J; Gordin A
    Clin Pharmacol Ther; 1990 Oct; 48(4):356-64. PubMed ID: 2225697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of nitecapone (OR-462) on the pharmacokinetics of levodopa and 3-O-methyldopa formation in cynomolgus monkeys.
    Cedarbaum JM; Léger G; Reches A; Guttman M
    Clin Neuropharmacol; 1990 Dec; 13(6):544-52. PubMed ID: 2276119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COMT inhibition with nitecapone does not affect the tyramine pressor response.
    Sundberg S; Gordin A
    Br J Clin Pharmacol; 1991 Jul; 32(1):130-2. PubMed ID: 1888633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycosulfatase activity of Helicobacter pylori towards gastric sulfomucin: effect of nitecapone.
    Slomiany BL; Murty VL; Piotrowski J; Morita M; Slomiany A
    J Physiol Pharmacol; 1993 Mar; 44(1):7-16. PubMed ID: 8518427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of human erythrocyte and gastroduodenal catechol-O-methyltransferase activity by nitecapone.
    Schultz E; Tarpila S; Bäckström AC; Gordin A; Nissinen E; Pohto P
    Eur J Clin Pharmacol; 1991; 40(6):577-80. PubMed ID: 1884738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal Structure of Catechol O-Methyltransferase Complexed with Nitecapone.
    Iijima H; Takebe K; Suzuki M; Kobayashi H; Takamiya T; Saito H; Niwa N; Kuwada-Kusunose T
    Chem Pharm Bull (Tokyo); 2020; 68(5):447-451. PubMed ID: 32378542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Helicobacter pylori glycosulfatase activity toward gastric sulfomucin by nitecapone.
    Murty VL; Piotrowski J; Morita M; Slomiany A; Slomiany BL
    Biochem Int; 1992 May; 26(6):1091-9. PubMed ID: 1632804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of ascorbate in protection by nitecapone against cardiac ischemia-reperfusion injury.
    Haramaki N; Stewart DB; Aggarwal S; Kawabata T; Packer L
    Biochem Pharmacol; 1995 Sep; 50(6):839-43. PubMed ID: 7575646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA.
    Doudet DJ; Chan GL; Holden JE; Pate BD; Morrison KS; Calne DB; Ruth TJ
    Eur J Pharmacol; 1997 Sep; 334(1):31-8. PubMed ID: 9346324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of the COMT inhibitor nitecapone for one week on exercise haemodynamics and catecholamine disposition.
    Sundberg S; Scheinin M; Ojala-Karlsson P; Akkila J; Gordin A
    Eur J Clin Pharmacol; 1993; 44(3):287-90. PubMed ID: 8491246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of gastric mucosal laminin receptor by Helicobacter pylori lipopolysaccharide: effect of nitecapone.
    Slomiany BL; Piotrowski J; Rajiah G; Slomiany A
    Gen Pharmacol; 1991; 22(6):1063-9. PubMed ID: 1839788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys.
    Miletich RS; Comi G; Bankiewicz K; Plunkett R; Adams R; Di Chiro G; Kopin IJ
    Brain Res; 1993 Oct; 626(1-2):1-13. PubMed ID: 8281420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antioxidant properties of nitecapone (OR-462).
    Suzuki YJ; Tsuchiya M; Safadi A; Kagan VE; Packer L
    Free Radic Biol Med; 1992 Nov; 13(5):517-25. PubMed ID: 1334029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Norepinephrine metabolites in plasma as indicators of pharmacological inhibition of monoamine oxidase and catechol O-methyltransferase.
    Scheinin M; Illi A; Koulu M; Ojala-Karlsson P
    Adv Pharmacol; 1998; 42():367-70. PubMed ID: 9327918
    [No Abstract]   [Full Text] [Related]  

  • 17. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.
    Kaakkola S; Gordin A; Männistö PT
    Gen Pharmacol; 1994 Sep; 25(5):813-24. PubMed ID: 7835624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of mucosal alkaline secretion in rat duodenum by dopamine and dopaminergic compounds.
    Flemström G; Säfsten B; Jedstedt G
    Gastroenterology; 1993 Mar; 104(3):825-33. PubMed ID: 8095035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of rat liver and duodenum soluble catechol-O-methyltransferase by a tight-binding inhibitor OR-462.
    Schultz E; Nissinen E
    Biochem Pharmacol; 1989 Nov; 38(22):3953-6. PubMed ID: 2597177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D1-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors.
    Vieira-Coelho MA; Gomes P; Serrão MP; Soares-da-Silva P
    Kidney Int; 2001 May; 59(5):1683-94. PubMed ID: 11318939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.